Status:
COMPLETED
Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients
Lead Sponsor:
Taipei Medical University WanFang Hospital
Collaborating Sponsors:
Far East Bio-Tec Co., Ltd
Conditions:
Chronic Hepatitis b
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
Hepatocellular carcinoma (HCC), listed among lung and breast cancers as the top-ten cancer in 2016 Taiwan, is the second most prevalent cancer, just one place below colon cancer. Due to mass hepatitis...
Detailed Description
Hepatocellular carcinoma (HCC), listed among lung and breast cancers as the top-ten cancer in 2016 Taiwan, is the second most prevalent cancer, just one place below colon cancer. Due to mass hepatitis...
Eligibility Criteria
Inclusion
- Patients with chronic hepatitis B do not take oral antiviral drugs.
- Ages between 20 and 75.
- High concentration of qHBsAg. qHBsAg≧1000 IU/ mL
Exclusion
- People allergic to seefood.
- Pregnancy
Key Trial Info
Start Date :
October 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04718831
Start Date
October 29 2019
End Date
November 30 2020
Last Update
January 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wanfang Hospital
Taipei, Wenshan District, Taiwan, 116